Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Biomarker analysis to unravel mechanisms of resistance to glofitamab monotherapy in large B cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

MHMartin Hutchings

Discussion

Loading...

Member takes

Overview

Biomarker analysis correlates tumor and TME features with treatment outcomes in R/R large B cell lymphoma, suggesting new resistance mechanisms for glofitamab.

Key Points

  • This research aims to investigate the relationship between tumor characteristics and treatment outcomes in patients with relapsed or refractory large B cell lymphoma receiving glofitamab monotherapy.
  • Analyzed patients with R/R large B-cell lymphoma in a Phase I/II study.
  • Used obinutuzumab pretreatment to manage cytokine release syndrome.
  • Conducted differential gene expression and gene set enrichment analyses to identify biomarkers related to outcomes.
  • Evaluated tumor responses using Lugano 2014 criteria.
  • Identified high tumor proliferation and related signatures in patients not achieving complete response.
  • Found significant associations between T cell markers and longer progression-free survival.
  • Revealed tumor microenvironment characteristics pivotal for treatment outcomes.

Cite This Study

Martin Hutchings (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db1dhttps://doi.org/10.1182/blood-2025-5316
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Analysis of factors associated with clinical response in glofitamab's treatment of relapsed or refractory (R/R) large B-cell lymphoma2025
  2. 2Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma2025
  3. 3Real-world efficacy, safety, and predictive factors for response to glofitamab in Chinese patients with relapsed/refractory aggressive B-cell lymphoma: A multicenter study2025
  4. 4Efficacy, safety, and T-cell population dynamics of glofitamab monotherapy in relapsed/refractory B-cell lymphoma2025
  5. 5A chemo-free tumor microenvironment (TME) reshaping regimen combining glofitamab induces a high CR rate in relapsed/refractory diffuse large B cell lymphoma (DLBCL)2025